Inhibitor of indoleamine-2,3-dioxygenase (ido)

Abstract

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

1 - 32 . (canceled) 
     
     
         33 . A method of treating a disease associated with IDO, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein:
 W is —O—, —S—, or a bond; 
 Q is —C(═O)NH— or a bond; 
 Y is —CR 8 ═ or —N═, as valency permits; 
 R 1  is —C(═O)OH, —C(═O)OR 10 , substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, —NHSO 2 R 9 , —C(═O)NHSO 2 R 9 , —C(═O)NHC(═O)OR 10 , or —SO 2 NHC(═O)R 10 ; 
 R 2  and R 3  are each independently hydrogen, halogen, substituted or unsubstituted C 1 -C 6  alkyl, substituted or unsubstituted C 1 -C 6  alkoxy, or R 2  and R 3  are joined to form a substituted or unsubstituted 3- to 8-membered carbocyclic ring, or substituted or unsubstituted 3- to 8-membered heterocyclic ring; 
 R 4  and R 5  are each independently hydrogen, substituted or unsubstituted C 1 -C 6  alkyl, substituted or unsubstituted C 2 -C 6  alkenyl, substituted or unsubstituted C 5 -C 8  cycloalkenyl, substituted or unsubstituted C 2 -C 10  alkynyl, substituted or unsubstituted C 1 -C 6  alkoxy, substituted or unsubstituted C 3 -C 5  cycloalkyl, substituted or unsubstituted 3- to 12-membered heterocyclyl, substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, substituted or unsubstituted aryl, or arylsulfonyl; or R 4  and R 5  are joined together with the N they are attached to to form optionally substituted, monocyclic or bicyclic, heterocyclyl; 
 R 6  is substituted or unsubstituted C 1 -C 6  alkyl, substituted or unsubstituted C 3 -C 8  cycloalkyl; substituted or unsubstituted C 2 -C 6  alkenyl, substituted or unsubstituted C 2 -C 6  alkynyl, substituted or unsubstituted C 5 -C 8  cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted 4- to 7-membered monocyclic heterocyclyl, substituted or unsubstituted 7- to 10-membered bicyclic heterocyclyl, substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl, substituted or unsubstituted 8- to 10-membered bicyclic heteroaryl, substituted or unsubstituted C 1 -C 6  alkoxy, substituted or unsubstituted aryloxy, or —C(═O)R 7 —; 
 R 7  is hydrogen, substituted or unsubstituted C 1 -C 6  alkyl, or substituted or unsubstituted aryl; 
 R 8  is hydrogen, halogen, —CN, —OH, substituted or unsubstituted C 1 -C 6  alkyl, or substituted or unsubstituted C 1 -C 6  alkoxy; and 
 R 9  and R 10  are each independently hydrogen, substituted or unsubstituted C 1 -C 6  alkyl, or substituted or unsubstituted C 2 -C 6  alkenyl. 
 
       
     
     
         34 . The method of  claim 33 , wherein the disease associated with IDO is cancer or an infectious disease. 
     
     
         35 . The method of  claim 33 , wherein the disease associated with IDO is cancer, which is selected from the group consisting of lung cancer, breast cancer, prostate cancer, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, head and neck cancer, renal cell carcinoma, esophageal cancer, pancreatic cancer, brain cancer, cancers of the gastrointestinal tract, liver cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, and osteosarcoma. 
     
     
         36 . The method of  claim 33 , further comprising treating the subject with another anti-cancer therapy. 
     
     
         37 . The method of  claim 36 , wherein the anti-cancer therapy is immunotherapy, radiation therapy, chemotherapy, cell therapy, surgery. 
     
     
         38 . The method of  claim 36 , wherein the anti-cancer therapy involves an anti-cancer agent. 
     
     
         39 . The method of  claim 33 , wherein the disease associated with IDO is an infectious disease. 
     
     
         40 . The method of  claim 39 , wherein the infectious disease is a viral infection and the subject is further treated with an additional anti-viral therapy. 
     
     
         41 . The method of  claim 40 , wherein the additional anti-viral therapy involves an additional anti-viral agent or anti-viral vaccine. 
     
     
         42 . (canceled)